This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tolleson, T. R. Articles by Tcheng, J. E. Search for Related Content PubMed PubMed Citation Articles by Tolleson, T. R. Articles by Tcheng, J. E.

Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention

observations from the ESPRIT trial

Thaddeus R. Tolleson, MD^*, J. Conor O’Shea, MD^*, John A. Bittl, MD, FACC, William B. Hillegass, MD, Kathryn A. Williams, MS^*, Glenn Levine, MD, Robert A. Harrington, MD, FACC^* and James E. Tcheng, MD, FACC^*,*

^* Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina, USA
Ocala Heart Institute, Ocala, Florida, USA
University of Alabama, Birmingham, Alabama, USA
Baylor College of Medicine, Houston, Texas, USA

View larger version (25K): [in a new window]   Figure 1 Clinical efficacy of the composite end point of death, myocardial infarction (MI), urgent target vessel revascularization (TVR), and bailout to open-label treatment for thrombosis; secondary end point of 30-day death, MI, and urgent TVR; and 48-h death or MI by tertile of index activated clotting time (ACT).

View larger version (19K): [in a new window]   Figure 2 Probability of 48-h death or myocardial infarction by index activated clotting time (ACT) for patients receiving treatment versus placebo in the ESPRIT trial.

View larger version (21K): [in a new window]   Figure 3 Major, minor, and the combination of major and minor bleeding (by TIMI criteria) by tertile of index activated clotting time (ACT).

View larger version (20K): [in a new window]   Figure 4 Probability of bleeding by index activated clotting time (ACT) for patients receiving treatment versus placebo in ESPRIT.

View larger version (14K): [in a new window]   Figure 5 Comparison of bleeding probabilities between IMPACT-II and ESPRIT patients receiving placebo. ACT = activated clotting time.

View larger version (14K): [in a new window]   Figure 6 Comparison of bleeding probabilities between IMPACT-II and ESPRIT patients receiving treatment. ACT = activated clotting time.